EPS Holdings, Inc. (EPLYF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EPS Holdings, Inc. (EPLYF) trades at $16.30. EPS Holdings, Inc. operates in the comprehensive support business, primarily focusing on the provision of services related to clinical trials and post-marketing activities for pharmaceutical companies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for EPLYF: EPLYF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EPLYF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on EPLYF.
How is this calculated? →EPS Holdings, Inc. (EPLYF) Healthcare & Pipeline Overview
EPS Holdings, Inc. provides comprehensive support services to pharmaceutical companies, focusing on clinical trials and post-marketing activities. Operating primarily in Japan and Asia, EPS Holdings differentiates itself through its integrated service offerings and established relationships with key pharmaceutical players, navigating a competitive landscape with increasing R&D outsourcing.
What Is the Investment Thesis for EPLYF?
EPS Holdings, Inc. presents an investment opportunity based on the growing trend of pharmaceutical companies outsourcing their clinical trial and post-marketing activities. The company's established presence in Japan and expanding footprint in Asia position it to capitalize on the increasing demand for outsourced services in these regions. Key value drivers include the company's ability to secure long-term contracts with major pharmaceutical players and its expertise in navigating the regulatory complexities of the pharmaceutical industry. However, potential risks include increased competition from other CROs and fluctuations in the demand for pharmaceutical services. Investors should monitor the company's ability to maintain its market share and expand its service offerings to sustain growth. The overall investment thesis hinges on the continued growth of the pharmaceutical outsourcing market and EPS Holdings' ability to capture a significant portion of this market.
Based on FMP financials and quantitative analysis
EPLYF Key Highlights
EPS Holdings, Inc. focuses on comprehensive support for pharmaceutical companies, covering clinical trials and post-marketing activities.
- The company operates primarily in Japan and Asia, leveraging its regional expertise.
- EPS Holdings offers integrated services, including clinical trial management, data management, and regulatory affairs.
- The company aims to streamline drug development for pharmaceutical clients, enhancing efficiency.
- EPS Holdings competes with other CROs and specialized service providers in the pharmaceutical support industry.
Who Are EPLYF's Competitors?
EPLYF is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASRPF Asarina Pharma AB (publ) | $2.45 | +0.00% | $41.8M | 43 |
| BBCP Concrete Pumping Holdings, Inc. | $8.98 | -0.55% | $453M | 54 |
| BNRPF Solon Eiendom ASA | $2.40 | +0.00% | $195M | 46 |
| CFWWF Calfrac Well Services Ltd. | $1.14 | -8.25% | $88.6M | 48 |
| FURGF Fugro N.V. | $10.58 | +0.00% | $1.15B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EPLYF's Key Strengths?
Comprehensive service offerings.
- Established presence in Japan.
- Expertise in regulatory affairs.
- Strong relationships with pharmaceutical companies.
What Are EPLYF's Weaknesses?
Limited geographic diversification.
- Dependence on the pharmaceutical industry.
- Potential for increased competition.
- Exposure to regulatory changes.
What Could Drive EPLYF Stock Higher?
Expansion into new geographic markets, particularly in Asia, could drive revenue growth.
- Development and launch of new service offerings, such as real-world evidence (RWE) generation, could attract new clients.
- Leveraging technology to improve efficiency and reduce costs could enhance profitability.
- Potential acquisitions of smaller CROs could expand service offerings and geographic reach.
- Positive regulatory developments in key markets could create new opportunities for pharmaceutical support services.
What Are the Key Risks for EPLYF?
Increased competition from other CROs could erode market share.
- Fluctuations in the demand for pharmaceutical services could impact revenue.
- Regulatory changes could increase compliance costs.
- Economic downturns could reduce pharmaceutical R&D spending.
- The company's OTC listing presents liquidity and transparency risks.
What Are the Growth Opportunities for EPLYF?
- Expansion into new geographic markets: EPS Holdings can expand its presence in emerging markets across Asia, where pharmaceutical R&D is growing rapidly. This expansion can be achieved through strategic partnerships and acquisitions, allowing the company to tap into new customer bases and service offerings. The market size for pharmaceutical support services in Asia is projected to reach $XX billion by 2028, presenting a significant growth opportunity for EPS Holdings.
- Development of new service offerings: EPS Holdings can develop new service offerings to address the evolving needs of pharmaceutical companies. This includes expanding into areas such as real-world evidence (RWE) generation and digital health solutions. By diversifying its service portfolio, EPS Holdings can attract new clients and increase its revenue per client. The market for RWE solutions in the pharmaceutical industry is expected to grow at a CAGR of XX% over the next five years.
- Leveraging technology to improve efficiency: EPS Holdings can leverage technology to improve the efficiency and effectiveness of its services. This includes implementing advanced data analytics and artificial intelligence (AI) to optimize clinical trial design and data management. By embracing technology, EPS Holdings can reduce costs, improve data quality, and accelerate the drug development process. The adoption of AI in clinical trials is projected to save the pharmaceutical industry $XX billion annually by 2027.
- Strengthening relationships with key pharmaceutical clients: EPS Holdings can strengthen its relationships with key pharmaceutical clients by providing customized solutions and exceptional service. This includes developing long-term partnerships and becoming a trusted advisor to its clients. By building strong relationships, EPS Holdings can secure repeat business and increase its market share. The lifetime value of a key pharmaceutical client can be significant, making relationship management a critical growth driver.
- Acquisition of smaller CROs: EPS Holdings can acquire smaller CROs to expand its service offerings and geographic reach. This includes acquiring companies with specialized expertise or a strong presence in specific markets. By acquiring smaller CROs, EPS Holdings can accelerate its growth and enhance its competitive position. The CRO industry is highly fragmented, presenting numerous acquisition opportunities for EPS Holdings.
What Are EPLYF's Competitive Advantages?
- Established relationships with key pharmaceutical players.
- Expertise in navigating the regulatory complexities of the pharmaceutical industry.
- Integrated service offerings spanning from clinical trials to post-marketing support.
- Strong presence in Japan and expanding footprint in Asia.
What Does EPLYF Do?
EPS Holdings, Inc. was founded with the mission to support pharmaceutical companies in their drug development and commercialization efforts. The company has evolved into a comprehensive support provider, offering services spanning from early-stage clinical trials to post-marketing surveillance. Its core business revolves around assisting pharmaceutical companies in navigating the complex regulatory and operational landscape of drug development. EPS Holdings' services include clinical trial management, data management, biostatistics, regulatory affairs, and marketing support. The company has established a strong presence in Japan and is expanding its reach across Asia. EPS Holdings aims to streamline the drug development process for its clients, enabling them to bring new therapies to market more efficiently. By providing a suite of integrated services, EPS Holdings positions itself as a strategic partner for pharmaceutical companies seeking to outsource their clinical and commercial operations. The company competes with other contract research organizations (CROs) and specialized service providers in the pharmaceutical industry.
What Products and Services Does EPLYF Offer?
- Provides clinical trial management services to pharmaceutical companies.
- Offers data management and biostatistics support for clinical studies.
- Assists with regulatory affairs and compliance for drug development.
- Provides post-marketing surveillance and support services.
- Offers marketing support for pharmaceutical products.
- Supports pharmaceutical companies in navigating the drug development process.
- Streamlines clinical and commercial operations for clients.
How Does EPLYF Make Money?
- Provides services to pharmaceutical companies on a contract basis.
- Generates revenue through fees for clinical trial management and support services.
- Secures long-term contracts with pharmaceutical clients.
- Expands service offerings to increase revenue per client.
What Industry Does EPLYF Operate In?
The pharmaceutical support services industry is experiencing growth driven by increasing R&D spending and the growing complexity of clinical trials. Pharmaceutical companies are increasingly outsourcing activities to CROs like EPS Holdings to reduce costs and improve efficiency. The competitive landscape includes global CROs and specialized service providers. EPS Holdings is positioned to benefit from the trend of outsourcing, particularly in the Asian market, where pharmaceutical R&D is growing rapidly. The industry is also influenced by regulatory changes and technological advancements in clinical trial management.
Who Are EPLYF's Key Customers?
- Pharmaceutical companies.
- Biotechnology companies.
- Medical device companies.
Company Profile
EPS Holdings, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. EPLYF has traded publicly since 2015.
EPLYF Financials
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EPLYF Latest News
No recent news available for EPLYF.
EPLYF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPLYF.
Price Targets
Wall Street price target analysis for EPLYF.
EPLYF MoonshotScore
What does this score mean?
The MoonshotScore rates EPLYF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Pharmaceutical Support ServicesEPLYF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EPS Holdings, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in less transparency and potentially greater volatility. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Shell Risk Detected.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal proceedings.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Verify the company's physical address and contact information.
- Check for independent audits of financial statements.
- Review the company's website and investor relations materials.
- Assess the company's industry reputation and customer reviews.
- Look for evidence of genuine business operations and revenue generation.
Common Questions About EPLYF (Healthcare)
What does EPS Holdings, Inc. do?
EPS Holdings, Inc. is a comprehensive support provider for pharmaceutical companies, specializing in clinical trials and post-marketing activities. The company offers a range of services, including clinical trial management, data management, biostatistics, regulatory affairs, and marketing support. EPS Holdings aims to streamline the drug development process for its clients, enabling them to bring new therapies to market more efficiently.
What do analysts say about EPLYF stock?
Analyst coverage of EPLYF is limited due to its OTC listing. Key valuation metrics are difficult to assess due to the lack of comprehensive financial disclosures. Growth considerations include the company's ability to expand its service offerings and geographic reach. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks. Analyst sentiment is not readily available due to the limited coverage and disclosure.
What are the main risks for EPLYF?
The main risks for EPS Holdings, Inc. include increased competition from other CROs, fluctuations in the demand for pharmaceutical services, and regulatory changes. The company's OTC listing also presents liquidity and transparency risks. Additionally, economic downturns could reduce pharmaceutical R&D spending, impacting the company's revenue. Investors should carefully consider these risks before investing in EPLYF. The Shell Risk detected also presents a significant risk factor that warrants careful investigation.
What are the key factors to evaluate for EPLYF?
Evaluate EPLYF on fundamentals, analyst consensus, and risk factors. EPS Holdings, Inc. presents an investment opportunity based on the growing trend of pharmaceutical companies outsourcing their clinical trial and post-marketing activities. Not financial advice.
How frequently does EPLYF data refresh on this page?
EPLYF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EPLYF's recent stock price performance?
EPS Holdings, Inc. (EPLYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EPLYF overvalued or undervalued right now?
EPS Holdings, Inc. (EPLYF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EPLYF before investing?
Before investing in EPS Holdings, Inc. (EPLYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and disclosure status.
- AI analysis pending for EPLYF.